NovaSight, an Airport City, Israel-based startup specializing in vision care solutions based on AI and eye tracking technology, closed its round A financing totaling $8M.
The round was led by Rimonci Capital and joined by strategic investors from both pharmaceutical and medical device industries. Prior to this round, the company raised $8M for a total of $16M.
The funds will be used to advance research in a large multi-center randomized pivotal study that will support FDA 510(k) clearance for its lazy eye treatment device and for the development of future eye care products such as innovative eye tracking based active glasses for myopia control.
Led by CEO Ran Yam, NovaSight focuses on bringing pediatric vision care into the digital age. It offers two flagship products:
– The CureSight™ system, an eye-tracking based lazy eye treatment intended to replace traditional eye patching. It is designed to provide cloud monitoring to caregivers and physicians while the child watches their content of choice from the comfort of home; and
– The EyeSwift® system, a comprehensive portable vision assessment device which accurately and objectively screens for multiple vision impairments within seconds.